Combination of Orally Inhaled BI1744CL/Tiotropium Bromide in Patients With Chronic Obstructive Pulmonary Disease ( COPD)

NCT00696020 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

360

Enrollment

INDUSTRY

Sponsor class

Conditions

Pulmonary Disease, Chronic Obstructive

Interventions

DRUG: BI 1744 CL/tiotropium bromide fixed dose combination
DRUG: tiotropium bromide
DEVICE: Respimat® Inhaler

Sponsor

Boehringer Ingelheim